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In humans, the most common genomic disorder is the hemizygous deletion of
the chromosome 22q11.2 region, that results in the “22q11.2 deletion syndrome”
(22q11.2DS). A peculiarity of 22q11.2DS is its great phenotypic variability that makes
this pathology a classic example of a syndrome with variable expressivity and incomplete
penetrance. The reasons for this variability have not been elucidated yet, and the
molecular substrates underlying the different clinical features of 22q11.2DS are still
debated. A cohort of 21 patients has been analyzed by array CGH in order to detect
some of the genetic differences that may influence this variability. Two aspects have
been investigated: (1) the precise localization of the deletion breakpoints within the low
copy repeats (LCRs), (2) the additional Copy Number Variations (CNVs) elsewhere in the
genome, by analyzing their gene content. Both protein-coding genes and miRNAs were
considered, in order to discover possible epistatic interactions between genes of the
22q11.2 region and the rest of the genome. Eighteen out of twenty-one patients had a
deletion of ∼3 Mb mediated by LCR22-A and D, whereas 3/21 had a smaller deletion.
The breakpoints within the LCR22-A and D do not have a major role in the phenotypic
variability since they are rather clustered and the small differences concern genes that are
not directly related to clinical signs of 22q11.2DS. A detailed analysis of the gene content
of 22q11.2 deleted region indicates that this syndrome could be a bioenergetic disorder
or consequence of an altered post-transcriptional gene regulation, due to the presence
of DGCR8, a major player of the microRNA (miRNA) biogenesis. Only four genes with
mitochondrial function are harbored in the additional CNVs, whereas 11 miRNA, all
related to biological pathways present in the 22q11.2DS, have been detected in 19/21
patients. CNVs and miRNAs are new entities that have changed the order of complexity
at the level of gene expression and regulation, thus CNV-miRNAs (miRNA harbored in the
CNVs) are potential functional variants that should be considered high priority candidate
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variants in genotype-phenotype association studies. Deletion of DGCR8, the main actor
in miRNA biogenesis, amplifies this variability. To our knowledge, this is the first report
that focus on the miRNA-CNVs in 22q11.2DS, with the aim of trying to better understand
their role in the variable expressivity and incomplete penetrance.
Keywords: 22q11 deletion syndrome, array CGH, copy number variations, miRNA, CNV-miRNA, DGCR8
INTRODUCTION
In humans, the most common genomic disorder is the
hemizygous deletion of the chromosome 22q11.2 region that
results in the “22q11.2 deletion syndrome” (22q11.2DS) (MIM
#188400/#192430), also referred to as Di George, Velocardiofacial
or Shprintzen syndrome.
A peculiarity of 22q11.2DS is its great phenotypic variability
that makes this pathology a classic example of a syndrome with
variable expressivity and incomplete penetrance.
22q11.2DS phenotype is characterized by a constellation
of clinical signs, whose characterization has expanded
considerably within the last decade. The phenotype includes
many associated findings such as congenital heart disease (CHD;
50–75%), hypocalcemia (17–60%), immunological disorders
(35–40%), palatal (69–100%), craniofacial (90%), skeletal
(17–19%), gastroenterological (35%) anomalies and a range of
neurocognitive, and psychiatric disorders (85%; McDonald-
McGinn and Sullivan, 2011). The severity of symptoms is also
variable, ranging from quite severe to near-normal life conditions
(Bassett et al., 2011). 22q11.2 deletion can be transmitted by
a normal parent with no clinically obvious phenotype, to
an affected child (Leana-Cox et al., 1996) and this provides
additional evidence that genetic modifiers, beyond the deleted
genes themselves, play a key role in determining the 22q11.2DS
phenotypic severity.
This variability can be due to stochastic and environmental
processes as well as to genetic effects, with all these factors
potentially acting alone or in combination. Currently, no
mechanistic explanation exists, and the reasons underlying this
phenotypic variability are still debated.
Extension of the deleted region could be a genetic
cause underlying the phenotypic variability. Deletions in
22q11.2 region are a consequence of non-allelic homologous
recombination (NAHR) due to misalignment of low copy
repeats (LCRs) during meiosis (Edelmann et al., 1999; Kumar
et al., 2008). Eight LCRs (named LRC22-A to H) have been
identified, but only the four centromeric ones (LCR22-A to D)
are implicated in this syndrome. Deletions mediated by different
specific LCRs will result in different sets of genes being deleted
and this is a cause of phenotypic variability. In any case, this does
not play a major role, since over 90% of patients share a deletion
between LCR22-A and LCR22-D.
Deletions that appear to have roughly the same size, since
mediated by the same couple of LCRs, may exhibit variability at
the sites of the NAHR event. A fine mapping of the breakpoints
within the LCRs has been performed only in a few studies
(Mantripragada et al., 2004; Urban et al., 2006; Bittel et al., 2009).
These small differences of the breakpoint localization within the
same LCR may influence the expression of genes that could have
a major role in the clinical phenotype of 22q11.2DS.
The presence of additional CNVs in the rest of the genome
could be another factor responsible for this variability. Human
genome is much more genetically variable than previously
appreciated. To date, nearly 10–15% of it has been annotated
as copy-number variations (CNVs), namely microdeletions and
microduplications, ranging from 1 kb to several Mb (Lee
et al., 2007). Their presence may contribute significantly toward
human phenotypic variability, complex behavioral traits, and
disease susceptibility.
Epistatic interactions between genes in the 22q11.2DS region
and other genes harbored in CNVs elsewhere in the genome
could explain the variable expressivity and reduced penetrance
of this syndrome.
According to the recent literature data, CNVs are a substantial
risk factor for a range of neurodevelopment and psychiatric
disorders such as autism, ADHD, schizophrenia, epilepsy, and
intellectual disability (Kirov et al., 2009; Cooper et al., 2011;
Vaishnavi et al., 2013).
In 22q11.2DS cases, a correlation between CNVs and
schizophrenia has been explored (Williams et al., 2013). However,
little is known about to the role of CNVs in modulating the
outcome of other phenotypic aspects of this syndrome. Two
recent articles focused on the role of CNVs as genetic modifiers
involved in the variable cardiac phenotype, studying a very large
cohort of 22q11.2 patients. Except for a common CNV, a SLC2A3
duplication, that was significantly associated with CHDs (cardiac
heart diseases), no differences were found in the number or in the
size of common CNVs between 22q11DS cases with or without
CHDs.
When rare CNVs were carefully examined for their gene
content and function, specific cardiac networks appeared to be
overrepresented in 22q11DS CHD cases but not in 22q11DS
controls with no cardiac phenotype (Mlynarski et al., 2015, 2016).
In this view, we focused our attention on these two genetic
factors as potential cause of variability, and, in particular (1) on
the localization of the deletion breakpoints within LCRs, (2) and
on the additional CNVs elsewhere in the genome, by analyzing
their gene content. Both protein-coding genes and microRNAs
(miRNAs) were evaluated, in order to discover possible epistatic
interactions between genes of the 22q11.2 region and the rest of
the genome.
MATERIALS AND METHODS
Subjects
Our study group consisted of 21 subjects with known
22q11.2 deletion who had been referred to our Institution for
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molecular-cytogenetic investigations (9 males, 12 females), with
age ranging from to 3 months to 37 years. This study was
approved by the Pediatric Committee of the Tuscany Region,
Meyer Hospital, Firenze, Italy. An informed consent was signed
prior to the genetic analyses. Main clinical aspects are reported in
Table 1.
Array-CGH
Genomic DNA of the patients was isolated from peripheral blood
by standard methods; DNA from healthy subjects (a male and a
female) was used as controls (Agilent Technologies, Santa Clara,
California, USA). Five-hundred nanograms of genomic DNA
both from the patient (test sample) and the control (reference
sample) were differentially labeled with Cy5-dCTP or with Cy3-
dCTP using random primer labeling according to manufacturer’s
protocol (Agilent). The labeling reactions were applied to the
oligo-arrays and incubated for 24 h at 67◦C in an oven. Slides
were washed and scanned using the Agilent scanner, and the
identification of individual spots on scanned arrays and quality
slide evaluation was performed using the Agilent dedicated
software (Feature Extraction, Agilent).
The array CGHwas performed on 180K SurePrint G3 Human
CGH Microarray (Agilent), that have a 13 KB overall median
probe spacing (11 KB in Refseq genes). In order to better
define the deletion breakpoints, we have also used 60K SurePrint
G3 Unrestricted CGH ISCA v2, that has a 60 KB overall
median probe spacing but higher in pathological or gene rich
regions.
Given that the quality of the experiment may greatly
influence the CNVs analysis (number and type of calls, probes
included/excluded from a call), in order to have more powerful
and clean data, we elaborated only those experiments that met the
“excellent” criteria as determined by theQC report (Cytogenomic
software, Agilent). In particular, the Derivative Log Ratio Spread
(DLRS) was the main value considered for further analysis of the
data: when >0.16, the experiment was discarded and repeated.
CNVs were identified with Cytogenomics 3.0.6.6. (Agilent), using
the Aberration Detection Method-2 (ADM-2) algorithm. This
algorithm identifies aberrant intervals in a sample that has
consistently high or low log ratios based on their statistical score.
The score represents the deviation of the weighted average of
the normalized log ratios from its expected value of zero and
incorporates quality information about each probemeasurement.
ADM-2 uses an iterative procedure to find all genomic intervals
with a score above a user/specified statistical threshold value. The
threshold was set to aminimumof six with theminimumnumber
of three probes required in a region and a minimum absolute
log ratio of 0.25. In particular, we have examined the 22q11.2
region, focusing on probes delimiting the breakpoints, together
with all the CNVs meeting the statistical parameter described
above. We analyzed all the CNVs >3 contiguous probes for
deletions and >4 probes for duplications, independently of
their absolute size; they were compared to those reported
in the http://dgv.tcag.ca/dgv/app/home. The gene content was
established by UCSC Genome Browser (http://genome.ucsc.
edu/) (NCBI37/hg19 assembly) and the gene function by RefSeq
(https://www.ncbi.nlm.nih.gov/refseq/rsg/).
Retrieval of CNV-microRNAs and Target
Prediction
The miRNA content in CNVs was identified by analyzing the
chromosomal coordinates in UCSC Genome Browser.
The function of these miRNAs and their validated and
putative targets were identified from the miRWalk database
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/).
miRWalk (Dweep et al., 2011) is a comprehensive database
that provides information on predicted as well as validated
binding sites of miRNAs on their target genes and the functional
patterns they are part of. For the prediction of putative targets by
miRWalk, filters were set and applied to identify the 3′UTR that
has a minimum seed match of seven nucleotides and retained
only the targets predicted by multiple databases (consistently
predicted by miRanda, miRDB, miRWalk, and TargetScan). This
integration between multiple databases improves the accuracy or
coverage of predictions by balancing out the precision and recall.
The biological pathways of genes targeted by these
miRNA were analyzed with Gene Ontology (GO; http://
www.geneontology.org/). GO has developed three structured
controlled vocabularies to describe gene products in terms of
their associated biological processes, cellular components and
molecular functions (Ashburner et al., 2000). All the related
functions associated with their enrichment scores and p-values
derived with the multiple test adjustment set were done by
Benjamini and Hochberg. Only the results with a corrected
p < 0.05 were considered to be significant. For each miRNA,
significative data on the biological process (GOBP) were
imported into a Microsoft Excel Table.
RESULTS
We analyzed 21 subjects with known 22q11.2 deletion using the
Agilent 180K whole genome and the 60K ISCA microarrays. A
scheme of the deletion extent is reported in Figure 1A. Eighteen
out of twenty-one patients had a 22q11.2 deletion of ∼3 Mb
mediated by LCR22-A andD, whereas 3/21 had smaller deletions,
of 1.3 Mb (pt. 19), 2.4 Mb (pt. 20), and 745 kb (pt. 21),
respectively.
In the 18 patients with the common ∼3 Mb deletion, using
the above sets of arrays, we were able to accurately define the
deletion boundaries. LCR22-A and D extend for 270 and 450
Kb, respectively, and harbor many genes (Figure 1B); the “gray
zone” (i.e., the region comprised between the last non-deleted
oligo and the first deleted one) was restricted to a small interval.
As far as the LCR22-A breakpoint is concerned, in three cases
(pt n.16,17,18) USP18 (Ubiquitin specific peptidase 18) was the
most proximal deleted gene with breakpoint boundaries limited
to a 10 Kb interval. In all the other patients, DGCR6 is the first
functional gene involved in the deletion since GGT3P (Gamma-
glutamyltransferase 3 pseudogene) is a pseudogene.
As far as the LCR22-D breakpoint is concerned, FAM230B
(Homo sapiens family with sequence similarity 230 member
B) is not deleted in patients 1–9, whereas it is in the “gray
zone” in the other nine cases (pts. 10–18). FAM230B is a
long non-protein coding RNA, with unknown functions. BCRP2
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(breakpoint cluster region pseudogene 2) that may represent a
difference in patients 1–9, is a pseudogene.
In the above 18 patients, the deleted region encompasses about
50 RefSeq genes, whose function has been well-established only in
a small proportion. There is an abundance of non-coding RNA
(a total of 13, 6 of which are miRNA) and nine genes (MRPL40,
PRODH, SLC25A1, TXNRD2, T10, ZDHHC, COMT, UFD1L,
DGCR8) that code for proteins, either localized to mitochondria
or connected to mithocondrial functions. DGCR8 (Di George
Critical Region Gene 8), in particular, is a gene that also has a
primary role in miRNA biogenesis.
CNVs
In our cohort, besides the 22q11.2 deletion, array CGH showed
the presence of additional CNVs. All the CNVs detected are
reported in Table 2, independently of their size, position, or gene
content; CNVs spanning segmental duplications were included,
since they are often gene rich. Both “rare” (when not reported
in normal population studies or with a frequency of <1%
in a previously published control populations) and “common”
(reported in several studies or with a frequence equal or higher
than 1% in the control populations) were considered (Pinto et al.,
2007; Vogler et al., 2010; Cooper andMefford, 2011; Cooper et al.,
2011; Coe et al., 2014).
The average number of CNVs per patient was 11; these CNVs
are present on all the chromosomes (except chromosome 19
and 20), with a size ranging from 9 kb to 2.1 Mb (average size
249 kb), and include roughly the same number of deletions and
duplications.
Among the 81 CNVs, 11 were rare, detected in 7 patients
(Table 2).
As far as their gene content is concerned, at first glance
it emerges that among the total amount of 177 RefSeq,
olfactory receptor, immunoglobulin family, HLA, and amylase
genes are the most represented, as expected. Fourteen genes,
both in common than in rare CNVs, are reported in
the OMIM database (https://www.omim.org/); four genes
related to mitochondrial function (IMMP2L, ACAD10,MRPS23,
CKMT1A) were detected. Interestingly, among the other genes,
there is a preponderance of miRNA (11). Nineteen out of 21
patients present at least one CNV-miRNA; some miRNAs are
present only in deleted CNVs (i.e., miRNA6891, miRNA4650-
2, miRNA5007, miRNA12331-1, miRNA1233-2), some only in
duplicated CNVs (miRNA3914-1, miRNA3914-2, miRNA6761,
miRNA650, miRNA6817, miRNA1256) and some in both
(miRNA3675, miRNA570; Tables 2, 3).
Functional Pathways of miRNA
These miRNAs regulate a large number of target genes, as
indicated by the miRWalk database (Dweep et al., 2011;
more than 400 entries, data not shown). Analyzing the
biological pathways with GO, only those significant (p <
0.05) were considered. Many entries are related to clinical
features of 22q11.2DS and we have grouped them into
nine macro-areas, including: phospho-calcium metabolism;
neurological, cardiovascular, immunity, cognitive-behavior, and
gastrointestinal pathways; ear-nose-throat, skeletal development.
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FIGURE 1 | (A) The deletion extent is shown for the 21 patients (bottom, black bars). On the top, a schematic representation of chromosome 22 is given. The four
Low Copy Repeats A to D (LCRA-D) involved in the deletion are indicated with white blocks. Cen is centromere; Tel is telomere. (B) Precise definition of the
breakpoints is shown for patients 1–18. On the top, a detailed structure of LCR A–D is shown, with the genes harbored and their positions (hg19 Genome Build). The
dark bars indicates the region deleted, the gray bars indicate the region that could or could not be deleted, with the probe positions.
As can be seen in Figure 2 and in Table 4, each miRNA has a
regulatory role on the genes that are involved in the vast majority
of these macro-areas.
DISCUSSION
As known, the clinical phenotype of 22q211.2DS is very variable
and it can be considered the prototype of those syndromes with
variable expressivity and reduced penetrance. The reasons for
this variability have not been elucidated yet, and the molecular
substrates underlying the different clinical features of 22q11.2DS
are still debated.
In consideration of this, we collected a cohort of 21 patients
and analyzed them by applying very homogeneous and strict
criteria, in order to detect some of the genetic differences that
may influence this variability. Two aspects were investigated:
(1) the precise breakpoint localization and (2) the additional
CNVs elsewhere in the genome in order to elucidate the possible
interactions between their genes and those in the 22q11.2 region.
Breakpoint Localization
According to the literature, it is known that the vast majority of
22q11.2 deletions happen between LCR22-A and D, giving rise
to the “common” ∼3 Mb deletion. Also in our cohort, 18/21 pts
have the deletion between A and D, whereas three cases have
smaller deletions (Figure 1B).
In the 18 patients sharing the ∼3 Mb deletion, the
fine mapping of the breakpoints within LCR22-A and D
allowed us to evaluate whether small differences of the gene
content at the boundaries may play a role in the clinical
variability of 22q.11.2 DS. Since LCR22-A and D are quite
large and harbor many genes, it is expected that a certain
variability could be present at the deletion sites. However,
the combination of two array CGH platforms surprisingly
showed that in our cohort the breakpoints localization is
rather clustered. The only difference concerns the USP18 and
FAM230B genes, at the proximal and at the distal breakpoint,
respectively.
USP18 (NM_017414) codes for a protein that belongs to
the ubiquitin-specific proteases (UBP) family of enzymes that
cleave ubiquitin from ubiquitinated protein substrates. Mice
lacking this gene are hypersensitive to interferon; in humans, no
data are available about its loss-of-function. FAM230B (Homo
sapiens family with sequence similarity 230 member B) is
a long non-protein coding RNA, the function of which is
unknown.
Even if our cohort is limited, it emerges from these data that
the breakpoints within the LCR22-A and D are clustered and
the small differences concern genes that are not directly related
to clinical signs of 22q11.2DS, thus it can be inferred that the
breakpoint localization does not have a major role in 22q11.2DS
phenotypic variability.
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TABLE 3 | The MiRNAs contained in the CNVs are shown in details.
Cytogenetic band 1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 21 miRNA
1p36.13 mirRNA3675
3q29 miRNA570
6p21.33 miRNA6891
7q11.22 X miRNA3914-1, miRNA3914-2
7q11.22–q11.23 miRNA4650-2
12q24.12–q24.13 miRNA6761
13q21.1 X miRNA5007
15q14 miRNA1233-1, miRNA1233-2
22q11.22 miRNA650
22q11.23–q12.1 miRNA6817
Xq22.2 miRNA1256
The cytogenetic band, the patient number, and the miRNA are indicated. Red box, deletion; Blue box, duplication; Yellow box, rare CNVs where the blue X indicates a duplication, and
a red X a deletion.
FIGURE 2 | Schematic representation of the biological pathways of the miRNA-CNVs. GO is the Gene ontology process. Only the results with a p < 0.05
were considered to be significant. Many entries were related to clinical features of 22q11.2DS; they were grouped them into nine macro-areas.
Additional CNVs and Their Gene Content
22q11.2DS patients show a wide spectrum of clinical signs,
but single aspects are recurrent (i.e., cardiological 50–75%,
immunological 35–40%, neurobehavioral 85%), and cannot be
related only to the presence of rare CNVs, which are defined as
having a frequency equal or <1% in control populations. For
this reason, in the present study, analysis of the gene content
was not limited to the rare CNVs, but was extended also to the
common ones. In Table 2, all the 81 CNVs detected in our cohort
are reported, regardless of their size or frequency, and their genes
content is shown.
Before discussing these results, it is worth noting that
additional CNVs represent a common background in all the
microdeletion syndromes, but most of them do not show
the phenotypic variability seen in the 22q11.2DS. If we
assume that CNVs could have a major impact on clinical
variability, we should address the reason why CNVs affect the
22q11.2DS phenotype more severely than other microdeletion
syndromes.
To find the genetic peculiarities that could justify such a
preponderant role of CNVs only in 22q11.2DS, first of all we
focused on the functional role of genes harbored in the 22q11.2
deleted region.
Peculiarity of the Genes in the 22q11.2 Region
The ∼3 Mb region encompasses about 50 RefSeq genes; many
of them have not been functionally well-characterized and little
is known about their contribution to single clinical aspects of
22q11DS. However, at first glance, the region contains a large
number of genes related to mitochondrial functions, and an
abundance of non-coding RNA (a total of 13, 6 of which are
miRNA) together with the presence of DGCR8 (Di George
Critical Region Gene 8), a gene with a primary role in miRNA
biogenesis.
Mitochondria and Embryonic development
During the embryo differentiation and early postnatal
development, cells actively divide, and these divisions require a
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TABLE 4 | Gene Ontology Biological Process (GOBP) of CNV-miRNA, with relation to the 22q11.2 deletion syndrome clinical signs.
miRNA Phospho-calcium
metabolism
Neurological
pathway
Cardiovascular
pathway
Skeletal
pathway
Immunity
pathway
Ear-nose-throat
development
Cognitive
pathway
Behavior
pathway
Gastrointestinal
pathway
miRNA 3675 X X X X X X X X
miRNA 570 X X X X X X X X
miRNA 6891 X X X X X X X X
miRNA 6761 X X X X X X X X
miRNA 650 X X X X X X X
miRNA 1256 X X X X X
miRNA 3914 1-2 X X X X X X
miRNA4650-2 X X X X X X X X
miRNA 5007 X X X X X X X X
miRNA 6817 X X X X X X X X X
miRNA 1233 X X X X X X X X X
TOT 11 11 11 11 10 8 8 8 6
The X indicates that a miRNA takes part to that process (p < 0.05).
great amount of energy, with intense mitochondrial activity; it is
expected that deficits in the bioenergetic machinery could set the
basis for pleiotropic effects in the majority of developing organs
and tissues.
Nine genes in 22q11.2 region code for proteins which
are either localized in the mitochondria or are connected
to mitochondrial functions (MRPL40, PRODH, SLC25A1,
TXNRD2, T10, ZDHHC, COMT, UFD1L, DGCR8) (Meechan
et al., 2011). 22q11.2DS is clearly due to an altered embryonal
development that compromises early morphogenesis in the
pharyngeal arches, heart, skeleton, and brain and thus it could
be the consequence of metabolic and energetic problems, rather
than of a decreased dosage of gene with a morphogenetic role.
Among the additional CNVs, four genes with mitochondrial
function (IMMP2L, ACAD10, MRPS23, and CKMT1A) have
been found. Even if our cohort is limited and it is not
possible to demonstrate a correlation between clinical variability
and mitochondrial pathways, a search for genes involved in
mitochondria has not been performed yet, and it should deserve
further attention in the future.
DGCR8 and CNV-miRNAs
DGCR8 has a primary role in miRNA biogenesis (Han et al.,
2004). MiRNAs exert a precise control over the spatiotemporal
expression of individual genes as well as large gene networks.
The way these tiny post-transcriptional gene regulators function
is not yet fully known. There is a functional redundancy,
since a single miRNA may have multiple mRNA targets, and
a target may be also regulated by multiple miRNAs. DGCR8
is a main actor in miRNA biogenesis, but alternative pathways
are known (Berezikov et al., 2007). Variations in miRNA
genes can severely affect downstream-regulated genes and their
pathways.
As expected, haploinsufficency of DGCR8 interferes with the
processing of many miRNAs, and it is clearly emerging that
some of phenotypic features of the 22q11.2DS could be ascribed
not only to haploinsufficiency of coding genes but to an altered
dosage of miRNAs.
In a knock-out mouse model, Dgcr8 hemizygosity causes
a 20–70% reduction in a subset of miRNAs in prefrontal
cortex and hippocampus with a consequent dysregulation of the
mRNA targets. Dgcr8+/− mice show behavioral and cognitive
dysfunction (Stark et al., 2008; Fénelon et al., 2011), present also
in the human 22q11.2DS (Schofield et al., 2011; Ouchi et al.,
2013). Dgcr8 is essential for miRNA biogenesis in embryonic
stem (ES) cells and regulates efficient ES-cell differentiation
(Wang et al., 2007). Cardiomyocyte-specific deletion ofDgcr8+/−
demonstrated downregulation of a subset of mature cardiac
enriched miRNAs; these mice experienced premature lethality
due to cardiac failure, pointing out a critical role for miRNAs
in maintaining cardiac function in mature cardiomyocytes (Rao
et al., 2009).
More recently, the human miRNA expression pattern in
the peripheral blood of 22q11.2DS has revealed a peculiar
profile that differs from that of the controls; the deregulated
miRNAs show a connection with the immunological, cardiac and
hypocalcemic pathways (de la Morena et al., 2013; Sellier et al.,
2014), suggesting that they may contribute to these phenotypic
aspects in 22q11.2DS. Interestingly, processing of miRNAs is not
globally altered in 22q11DS, but limited to the DGCR8 targets,
providing compelling evidence of specific miRNA DGCR8-
mediated dysregulation (Sellier et al., 2014).
In view of this, the role of the CNVs on the phenotypic
variability of 22q11.2DS could be correlated non just to protein
coding genes, but to miRNA gene content. Most of the studies
that have dealt with CNVs and 22q11.2DS variability have been
focused only on the protein coding genes, and the impact
of altered dosage of non-coding regulatory miRNAs is largely
unexplored.
Recently, some articles have highlighted a consistent co-
localization of miRNA loci with CNV regions (CNV-miRNAs)
(Marcinkowska et al., 2011; Veerappa et al., 2014). In a study on
1,715 subjects, about 5% of all miRNAs are harbored in the CNVs,
∼9% of CNVs were shown to harbor miRNA genes and these
CNV-miRNAs were identified in 83.8% individuals (Veerappa
et al., 2014).
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In our cohort, 11 CNV-miRNAs were identified (Table 3): as
can be seen, some miRNAs are deleted, some duplicated, some
others are present both in deletions and in duplications.
It seems obvious that the expression of miRNAs correlates
with the CNV dose, as the expression of protein-coding genes
depends on the copy number. CNV-miRNA with one allele
duplicated (copy number = 3) or deleted (copy number = 1) is
expected to have a level of expression roughly 1.5 or 0.5 times,
respectively, compared to the wild type (copy number = 2). A
change in a miRNA dosage will affect the expression of all of its
target genes and may have a pleiotropic effect.
In 22q11.2DS patients, where DGCR8 activity is reduced by
about 50% (Sellier et al., 2014), the expression pattern of CNV-
miRNAs is completely dysregulated. The dosage of a miRNA
in a deleted CNV is further decreased, whereas the dosage of
miRNA in a duplicated CNV could be compensated by DGCR8
hemizygosity. This dysregulation take place simultaneously on all
miRNAs of an individual according to his CNV background.
It is worth noting that all the 11 miRNAs detected in the
present cohort of patients have a biological role in pathways
related to some phenotypic characteristics of 22q11.2DS
(Table 4).
These changes in miRNAs expression are likely to contribute
significantly toward 22q11.2DS phenotypic variability. Therefore,
DGCR8 could represent the genetic particularity according to
which the additional CNVs affect the 22q11.2DS phenotypemore
greatly than other microdeletion syndromes.
In view of this, 22q11.2DS could be mainly related to a
dysregulation of post-transcriptional modifications that lead to
an altered dosage of proteins crucial for phenotype development.
CONCLUDING REMARKS
In this paper some of the genetic factors that can influence
22q11.2DS variability have been analyzed, and, even if the cohort
of patients is limited, interesting observations can be made.
22q11.2 breakpoints are rather clustered, and it is unlikely that
they play a major role in the variability.
A detailed analysis of the gene content of 22q11.2 deleted
region indicates that this syndrome could be a metabolic
disorder or consequence of altered post-transcriptional gene
modifications.
In the additional CNVs, four genes with mitochondrial
functions and 11 miRNAs, all related to the biological pathways
present in the 22q11.2DS, have been detected in 4/21 and in19/21
patients, respectively.
CNVs and miRNAs are new entities that have changed the
order of complexity at the level of gene expression and regulation,
thus CNV-miRNAs are potential functional variants that should
be considered high priority candidate variants in genotype-
phenotype association studies. Deletion of DGCR8, the main
actor in miRNA biogenesis, amplifies this variability.
To our knowledge, this is the first report that focuses on the
CNV-microRNAs in 22q11.2DS, with the aim of trying to better
understand their role in the variable expressivity and reduced
penetrance.
In the near future, it will be important to characterize the
pathways of these CNV-miRNAs in a much more comprehensive
manner in order to improve the genetic networks that can
contribute to the pathophysiology of 22q11.2.
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